{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:53:15Z","timestamp":1781643195875,"version":"3.54.5"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Egyptian Russian University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    A rapid and efficient High-Performance Liquid Chromatography (HPLC) method was developed and optimized for the separation and quantification of solifenacin succinate (SOL), mirabegron (MIR), solifenacin impurities A (SOL IMP A), I (SOL IMP I) and mirabegron metabolite (MIR MET) using a C\n                    <jats:sub>18<\/jats:sub>\n                    column. Solifenacin succinate is a muscarinic receptor antagonist used in the treatment of overactive bladder (OAB) by reducing bladder muscle contractions, while mirabegron, a \u03b23-adrenergic agonist, works by relaxing the bladder smooth muscle to improve storage capacity and reduce symptoms of OAB. However, the presence of impurities and metabolites, such as solifenacin impurities A, I, and E, can negatively impact the safety and efficacy of these drugs, potentially causing adverse effects such as increased toxicity, altered pharmacodynamics, or diminished therapeutic effectiveness. The method employed an isocratic elution system with a mobile phase of water containing 0.1% formic acid (solvent A) and acetonitrile with 0.1% formic acid (solvent B), using a C\n                    <jats:sub>18<\/jats:sub>\n                    column (4.6\u00a0mm \u00d7 100\u00a0mm, 3\u00a0\u03bcm) at a flow rate of 1.2 mL\/min and a column temperature of 30\u00a0\u00b0C. UV detection at 220\u00a0nm allowed for the efficient separation of all analytes within 10.5\u00a0min, with excellent resolution between solifenacin succinate, mirabegron, their metabolites, and impurities. The linearity range for solifenacin succinate and mirabegron was 1\u2013100\u00a0\u00b5g\/mL, and solifenacin impurities A, I, and E, and mirabegron metabolite exhibited linearity ranges of 0.1\u201310 and 0.1\u201350\u00a0\u00b5g\/mL, respectively. Validation studies confirmed good precision (RSD\u2009&lt;\u20092%) and accuracy, making this method suitable for routine quality control and pharmacokinetic studies. This validated HPLC method offers a reliable tool for monitoring the purity of solifenacin succinate and mirabegron, ensuring their therapeutic efficacy and safety by quantifying both the active compounds and potentially harmful impurities or metabolites.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-39569-2","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T19:01:26Z","timestamp":1773428486000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Validated comprehensive RP HPLC approach for separation and quantification of solifenacin and mirabegron in the presence of their degradation products"],"prefix":"10.1038","volume":"16","author":[{"given":"Ebraam B.","family":"Kamel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Badrawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israa M.","family":"Nour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"39569_CR1","unstructured":"United States Pharmacopeia (USP) 42. \u2018Solifenacin succinate monograph.\u2019 USP-NF. https:\/\/www.usp.org\/ (2019)."},{"key":"39569_CR2","unstructured":"European Pharmacopoeia (EP) 10th edition. \u2018Solifenacin succinate monograph.\u2019 Council of Europe. https:\/\/www.edqm.eu\/ (2020)."},{"key":"39569_CR3","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1442-2042.2005.01001.x","volume":"12","author":"P Tosukhowong","year":"2005","unstructured":"Tosukhowong, P., Tungsanga, K., Phongudom, S. & Sriboonlue, P. Effects of potassium-magnesium citrate supplementation on cytosolic ATP citrate lyase and mitochondrial aconitase activity in leukocytes: A window on renal citrate metabolism. Int. J. Urol. 12, 140\u2013144 (2005).","journal-title":"Int. J. Urol."},{"key":"39569_CR4","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1002\/jssc.202100980","volume":"45","author":"EB Kamel","year":"2022","unstructured":"Kamel, E. B. Two green chromatographic methods for the quantification of Tamsulosin and Solifenacin along with four of their impurities. J. Sep. Sci. 45, 1305\u20131316 (2022).","journal-title":"J. Sep. Sci."},{"key":"39569_CR5","doi-asserted-by":"publisher","first-page":"e23632","DOI":"10.1002\/chir.23632","volume":"36","author":"N Vadagam","year":"2024","unstructured":"Vadagam, N., Haridasyam, S. B., Venkatanarayana, M., Lakka, N. S. & Chinnakadoori, S. R. Separation and simultaneous Estimation of enantiomers and diastereomers of muscarinic receptor antagonist Solifenacin using stability-indicating Normal\u2010phase HPLC technique with chiral stationary phase amylose tris\u2010(3, 5\u2010dimethylphenylcarbamate). Chirality 36, e23632 (2024).","journal-title":"Chirality"},{"key":"39569_CR6","first-page":"289","volume":"64","author":"R Totos","year":"2019","unstructured":"Totos, R., Balazsi, J. & Validated LC-MS\/MS method for the determination of the muscarinic receptor antagonist (MRA) Solifenacin from human plasma. Stud. Univ. Babes-Bolyai Chem. 64, 289\u2013297 (2019).","journal-title":"Stud. Univ. Babes-Bolyai Chem."},{"key":"39569_CR7","first-page":"4343","volume":"4","author":"DS Israel","year":"2013","unstructured":"Israel, D. S., Krishnachaitanya, K. & Gowrisankar, D. RP-HPLC method for the Estimation of Tamsulosin and Solifenacin in bulk and its dosage forms. Int. J. Pharm. Sci. Res. 4, 4343 (2013).","journal-title":"Int. J. Pharm. Sci. Res."},{"key":"39569_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s10337-015-3007-7","volume":"79","author":"DK Singh","year":"2016","unstructured":"Singh, D. K., Kurmi, M., Handa, T. & Singh, S. LC\u2013MS\/TOF, LC\u2013MS n and H\/D exchange studies on Solifenacin succinate targeted to characterize its forced degradation products. Chromatographia 79, 159\u2013168 (2016).","journal-title":"Chromatographia"},{"key":"39569_CR9","doi-asserted-by":"publisher","first-page":"2200117","DOI":"10.1002\/sscp.202200117","volume":"6","author":"S Dhiman","year":"2023","unstructured":"Dhiman, S., Kurmi, B., Das & Asati, V. Analytical reversed-phase high\u2010performance liquid chromatography method development for silodosin and Solifenacin in bulk and marketed formulation using analytical quality by design approach. Sep. Sci. Plus. 6, 2200117 (2023).","journal-title":"Sep. Sci. Plus"},{"key":"39569_CR10","first-page":"602","volume":"3","author":"MM Annapurna","year":"2014","unstructured":"Annapurna, M. M., Sowjanya, G., Naidu, M. S. & Lohithasu, D. A validated liquid chromatographic method for the determination of Solifenacin succinate (Urinary antispasmodic) in tablets. Chem. Sci. Trans. 3, 602\u2013607 (2014).","journal-title":"Chem. Sci. Trans."},{"key":"39569_CR11","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1093\/chromsci\/48.10.807","volume":"48","author":"SR Krishna","year":"2010","unstructured":"Krishna, S. R., Rao, B. & Rao, N. S. A validated rapid stability- indicating method for the determination of related substances in Solifenacin succinate by ultra-fast liquid chromatography. J. Chromatogr. Sci. 48, 810\u2013813 (2010).","journal-title":"J. Chromatogr. Sci."},{"key":"39569_CR12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1556\/1006.2019.32.4.7","volume":"32","author":"DA Shah","year":"2019","unstructured":"Shah, D. A., Tahilramani, P. J., Patel, V. B. & Chhalotiya, U. High-performance thin-layer chromatographic method for the Estimation of mirabegron and Solifenacin succinate used in the treatment of overactive bladder syndrome. JPC\u2013Journal Planar Chromatogr. TLC. 32, 323\u2013327 (2019).","journal-title":"JPC\u2013Journal Planar Chromatogr. TLC"},{"key":"39569_CR13","doi-asserted-by":"crossref","unstructured":"Reddy, B. V. R., Reddy, B. S., Raman, N., Reddy, K. S. & Rambabu, C. Development and validation of a specific stability indicating high performance liquid chromatographic methods for related compounds and assay of solifenacin succinate. J. Chem. 412353 (2013).","DOI":"10.1155\/2013\/412353"},{"key":"39569_CR14","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1016\/j.jchromb.2010.10.010","volume":"878","author":"J Macek","year":"2010","unstructured":"Macek, J., Pt\u00e1\u010dek, P. & Kl\u00edma, J. Determination of Solifenacin in human plasma by liquid chromatography\u2013tandem mass spectrometry. J. Chromatogr. B. 878, 3327\u20133330 (2010).","journal-title":"J. Chromatogr. B"},{"key":"39569_CR15","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s10337-020-03929-5","volume":"83","author":"RA Jadhav","year":"2020","unstructured":"Jadhav, R. A. et al. Development and validation of rapid Stability-Indicating RP-HPLC method for assay and related substances of Solifenacin succinate. Chromatographia 83, 1107\u20131119 (2020).","journal-title":"Chromatographia"},{"key":"39569_CR16","doi-asserted-by":"crossref","unstructured":"Eissa, M. S., Kamel, E. B., Hegazy, M. A. & Fayed, A. S. Expeditive chromatographic methods for quantification of solifenacin succinate along with its official impurity as the possible acid degradation product. J. Chromatogr. Sci. 1\u20137 (2023).","DOI":"10.1093\/chromsci\/bmac111"},{"key":"39569_CR17","doi-asserted-by":"publisher","first-page":"104905","DOI":"10.1016\/j.microc.2020.104905","volume":"157","author":"MA Tantawy","year":"2020","unstructured":"Tantawy, M. A., Weshahy, S. A., Wadie, M. & Rezk, M. R. Stability-indicating HPTLC method for the simultaneous detection and quantification of Alfuzosin hydrochloride, Solifenacin succinate along with four of their official impurities. Microchem J. 157, 104905 (2020).","journal-title":"Microchem J."},{"key":"39569_CR18","first-page":"310","volume":"3","author":"D Desai","year":"2011","unstructured":"Desai, D., Mehta, G., Ruikar, D., Jain, R. & Rajput, S. Development and validation of Stability-Indicating HPTLC method of Solifenacin succinate. Asian J. Pharm. Biol. Res. (AJPBR. 3, 310\u2013316 (2011).","journal-title":"Asian J. Pharm. Biol. Res. (AJPBR"},{"key":"39569_CR19","doi-asserted-by":"publisher","first-page":"101095","DOI":"10.1016\/j.scp.2023.101095","volume":"33","author":"M Wadie","year":"2023","unstructured":"Wadie, M., Abdel-Moety, E. M., Rezk, M. R. & Marzouk, H. M. Sustainable and smart HPTLC determination of silodosin and Solifenacin using a constructed two illumination source chamber with a smartphone camera as a detector: comparative study with conventional densitometric scanner. Sustain. Chem. Pharm. 33, 101095 (2023).","journal-title":"Sustain. Chem. Pharm."},{"key":"39569_CR20","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1093\/jaoacint\/qsad065","volume":"106","author":"N Ashrafi","year":"2023","unstructured":"Ashrafi, N., Sohrabi, M. R. & Saber Tehrani, M. Comparative study of continuous wavelet transform and multivariate calibration for the simultaneous spectrophotometric determination of Tamsulosin and Solifenacin in pharmaceutical formulation and biological sample. J. AOAC Int. 106, 1620\u20131628 (2023).","journal-title":"J. AOAC Int."},{"key":"39569_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.56431\/p-0t227j","volume":"10","author":"BSV Seshamamba","year":"2013","unstructured":"Seshamamba, B. S. V., Satyanarayana, P. V. V. & Sekaran, C. B. Development and validation of spectrophotometric methods for the quantification of Solifenacin succinate: application to tablet dosage forms. Int. Lett. Chem. Phys. Astron. 10, 167\u2013182 (2013).","journal-title":"Int. Lett. Chem. Phys. Astron."},{"key":"39569_CR22","first-page":"1752","volume":"23","author":"L Singh","year":"2011","unstructured":"Singh, L. & Nanda, S. Spectrophotometric determination of Solifenacin succinate through ion association complex formation in bulk sample and pharmaceutical formulations. Asian J. Chem. 23, 1752\u20131754 (2011).","journal-title":"Asian J. Chem."},{"key":"39569_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.21608\/aprh.2022.161245.1191","volume":"7","author":"M Abdel Moneim","year":"2023","unstructured":"Abdel Moneim, M. & Simultaneous Spectrophotometric & spectrofluorimetric assay of silodosin & Solifenacin in their Co-formulated binary mixture. J. Adv. Pharm. Res. 7, 15\u201320 (2023).","journal-title":"J. Adv. Pharm. Res."},{"key":"39569_CR24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/jaoacint\/qsab080","volume":"105","author":"AS Fayed","year":"2022","unstructured":"Fayed, A. S., Hegazy, M. A., Kamel, E. B. & Eissa, M. S. Smart mathematical manipulation of spectral signals: stability Indicating, for the Estimation of Solifenacin succinate: Anti-Muscarinic Drug, in existence of its acid degradation product. J. AOAC Int. 105, 223\u2013231 (2022).","journal-title":"J. AOAC Int."},{"key":"39569_CR25","doi-asserted-by":"publisher","first-page":"122442","DOI":"10.1016\/j.saa.2023.122442","volume":"293","author":"RA Sayed","year":"2023","unstructured":"Sayed, R. A., Mohamed, A. R., Shalaby, A. & Ibrahim, H. Micellar-enhanced and green-assessed first-derivative synchronous spectrofluorimetric approach for concurrent determination of Alfuzosin hydrochloride and Solifenacin succinate in different matrices: Docking simulation. Spectrochim Acta Part. Mol. Biomol. Spectrosc. 293, 122442 (2023).","journal-title":"Spectrochim Acta Part. Mol. Biomol. Spectrosc."},{"key":"39569_CR26","unstructured":"Alia Afra, S. et al. A new spectrophotometric method for the determination of Solifenacin in pure form and in pharmaceutical formulations."},{"issue":"1","key":"39569_CR27","first-page":"58","volume":"109","author":"CR o Chapple","year":"2012","unstructured":"Chapple, C. R. & Vardy, K. Mirabegron, a new \u03b23-adrenoceptor agonist: the role in overactive bladder treatment. Br. J. Urol. Int. 109 (1), 58\u201368 (2012).","journal-title":"Br. J. Urol. Int."},{"issue":"2","key":"39569_CR28","first-page":"57","volume":"7","author":"S o Herschorn","year":"2015","unstructured":"\u00a0Herschorn, S. The Pharmacology of mirabegron: A \u03b23-adrenoceptor agonist for the treatment of overactive bladder. Ther. Adv. Urol. 7 (2), 57\u201364 (2015).","journal-title":"Ther. Adv. Urol."},{"issue":"3","key":"39569_CR29","first-page":"304","volume":"20","author":"H o Lee","year":"2015","unstructured":"Lee, H. & Kim, H. Quantification and impurity profiling of mirabegron in pharmaceutical formulations by HPLC. Pharm. Dev. Technol. 20 (3), 304\u2013311 (2015).","journal-title":"Pharm. Dev. Technol."},{"key":"39569_CR30","doi-asserted-by":"publisher","first-page":"115937","DOI":"10.1016\/j.jpba.2023.115937","volume":"240","author":"Y Lou","year":"2024","unstructured":"Lou, Y. et al. Simultaneous quantification of mirabegron and vibegron in human plasma by HPLC-MS\/MS and its application in the clinical determination in patients with tumors associated with overactive bladder. J. Pharm. Biomed. Anal. 240, 115937 (2024).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"39569_CR31","doi-asserted-by":"publisher","first-page":"101523","DOI":"10.1016\/j.scp.2024.101523","volume":"39","author":"P Prajapati","year":"2024","unstructured":"Prajapati, P. et al. Green LC-MS\/MS method for in-vivo pharmacokinetics of mirabegron-encapsulated nanostructured lipid carriers in rat plasma: integrating white analytical chemistry and analytical quality by design approach. Sustain. Chem. Pharm. 39, 101523 (2024).","journal-title":"Sustain. Chem. Pharm."},{"key":"39569_CR32","first-page":"36","volume":"1","author":"M Rezaei","year":"2018","unstructured":"Rezaei, M. & Ramazani, A. RP-HPLC method development and validation for the quantitative Estimation of mirabegron in extended-release tablets. J. Med. Chem. Sci. 1, 36\u201340 (2018).","journal-title":"J. Med. Chem. Sci."},{"key":"39569_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1590\/1806-9282.65.2.141","volume":"65","author":"L Chen","year":"2019","unstructured":"Chen, L. & Zhang, Y. Determination of mirabegron in rat plasma by UPLC\u2013MS\/MS after oral and intravenous administration. Rev. Assoc. Med. Bras. 65, 141\u2013148 (2019).","journal-title":"Rev. Assoc. Med. Bras."},{"key":"39569_CR34","doi-asserted-by":"crossref","unstructured":"Mishra, S., Surekha, N. & Chauhan, A. Development and validation of stability indicating RP-HPLC method for simultaneous Estimation of silodosin and mirabegron in synthetic mixture. Ann. Pharmaceut. Fran\u00e7aises 82 243\u2013262 (2024).","DOI":"10.1016\/j.pharma.2023.12.013"},{"key":"39569_CR35","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.3109\/03639045.2013.810634","volume":"40","author":"H Mahgoub","year":"2014","unstructured":"Mahgoub, H., Youssef, R. M., Korany, M. A., Khamis, E. F. & Kamal, M. F. Development and validation of spectrophotometric and HPTLC methods for simultaneous determination of Rosiglitazone maleate and Metformin hydrochloride in the presence of interfering matrix excipients. Drug Dev. Ind. Pharm. 40, 1190\u20131198 (2014).","journal-title":"Drug Dev. Ind. Pharm."},{"key":"39569_CR36","doi-asserted-by":"publisher","first-page":"111862","DOI":"10.1016\/j.microc.2024.111862","volume":"207","author":"P Prajapati","year":"2024","unstructured":"Prajapati, P. et al. Microwave-aided sensitive and eco-friendly HPTLC method for Estimation of mirabegron using NBD-Cl as bio-sensing fluorescent probe by integration of principal component Analysis, response surface modelling and white analytical chemistry approach. Microchem J. 207, 111862 (2024).","journal-title":"Microchem J."},{"key":"39569_CR37","doi-asserted-by":"crossref","unstructured":"Dhamal, C. H., Kachhot, K. D., Vaghela, F. H. & Joshi, H. S. UV-Vis spectrophotometric method development and validation of mirabegron via green approach. J Appl. Spectrosc. 1\u20138 (2024).","DOI":"10.1007\/s10812-024-01827-4"},{"key":"39569_CR38","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1134\/S1061934818090095","volume":"73","author":"RK Papanna","year":"2018","unstructured":"Papanna, R. K., Gowda, J. B. K. & Nagaraja, P. An experimental design approach for optimization of spectrophotometric Estimation of mirabegron in bulk and pharmaceutical formulations. J. Anal. Chem. 73, 884\u2013893 (2018).","journal-title":"J. Anal. Chem."},{"key":"39569_CR39","doi-asserted-by":"crossref","unstructured":"Derayea, S. M., Ahmed, A. S., Abdelshakour, M. A., Oraby, M. & El-Din, K. M. B. Diaryl pyrrolone fluorescent probing strategy for mirabegron determination through condensation with ninhydrin and phenylacetaldehyde: application to dosage forms, human urine and plasma. Spectrochim. Acta Part. Mol. Biomol. Spectrosc. 124515 (2024).","DOI":"10.1016\/j.saa.2024.124515"},{"key":"39569_CR40","doi-asserted-by":"publisher","first-page":"100976","DOI":"10.1016\/j.scp.2023.100976","volume":"32","author":"RA Sayed","year":"2023","unstructured":"Lotfy, H. M., Obaydo, R. H. & Mouhamed, A. A. GLANCE visualization for smart analytical chemistry methods: artificial intelligence for spectrophotometric determination of solifenacin-mirabegron combination. Sustain. Chem. Pharm. 47, 102159 (2025).","journal-title":"Sustain. Chem. Pharm."},{"key":"39569_CR41","doi-asserted-by":"publisher","first-page":"110258","DOI":"10.1016\/j.microc.2024.110258","volume":"200","author":"EA Bahgat","year":"2024","unstructured":"Bahgat, E. A., Saleh, H., Hendawy, H. A. M. & Darwish, I. M. Challenging electroanalytical method for the determination of mirabegron in biological samples and pharmaceutical formulations. Microchem J. 200, 110258 (2024).","journal-title":"Microchem J."},{"key":"39569_CR42","doi-asserted-by":"publisher","first-page":"23138","DOI":"10.1039\/D3RA02343E","volume":"13","author":"AA Mouhamed","year":"2023","unstructured":"Mouhamed, A. A., Eltanany, B. M., Mostafa, N. M., Elwaie, T. A. & Nadim, A. H. Design of screen-printed potentiometric platform for sensitive determination of mirabegron in spiked human plasma; molecular Docking and transducer optimization. RSC Adv. 13, 23138\u201323146 (2023).","journal-title":"RSC Adv."},{"key":"39569_CR43","first-page":"2652","volume":"20","author":"G Andhale","year":"2022","unstructured":"Andhale, G., Shankarpure, M., Kadam, J., Shelar, M. & Singh, S. RP-HPLC method development and validation for the simultaneous Estimation of mirabegron and Solifenacin succinate in pharmaceutical dosage form. NeuroQuantology 20, 2652 (2022).","journal-title":"NeuroQuantology"},{"key":"39569_CR44","unstructured":"Kadam, M. M. M., Singh, R. P. & Charde, M. S. Development and validation of stability indicating UHPLC method for the quantitative Estimation of mirabegron and Solifenacin succinate in pharmaceutical dosage form. J. Pharm. Negat. Res. 6727\u20136737 (2023)."},{"key":"39569_CR45","doi-asserted-by":"publisher","first-page":"123644","DOI":"10.1016\/j.saa.2023.123644","volume":"307","author":"IM Nour","year":"2024","unstructured":"Godge, R., Shinde, G. & Gore, R. Simultaneous estimation of solifenacin and mirabegron in bulk drug and tablet dosage form by RP-HPLC method. Res. J. Pharm. Technol. 18, 3236\u20133239 (2025).","journal-title":"Spectrochim Acta Part. Mol. Biomol. Spectrosc."},{"key":"39569_CR46","first-page":"223","volume":"2","author":"J Patel","year":"2022","unstructured":"Patel, J., Patel, G. & Meshram, D. Development and validation of UV and RP-HPLC methods for simultaneous Estimation of mirabegron and Solifenacin succinate in their pharmaceutical dosage form. Med. Sci. 2, 223\u2013232 (2022).","journal-title":"Med. Sci."},{"key":"39569_CR47","unstructured":"Bairam, R. et al. Analytical Quality by Design Approach in RP-HPLC Method Development for the Quantification of Mirabegron and Solifenacin Succinate in Pharmaceutical Formulation. (2024)."},{"key":"39569_CR48","unstructured":"Guideline, I. C. H. Stability Testing of New Drug Substances and Products Q1A (R2), Current Step 4 version dated 6 February 2003."},{"key":"39569_CR49","doi-asserted-by":"crossref","unstructured":"Zarzycki, P. K. Staining and derivatization techniques for visualization in planar chromatography. in Instrumental thin-layer chromatography 213\u2013257 (Elsevier, 2023).","DOI":"10.1016\/B978-0-323-99970-0.00013-2"},{"key":"39569_CR50","first-page":"102","volume":"5","author":"CCA Loures","year":"2013","unstructured":"Loures, C. C. A. et al. Advanced oxidative degradation processes: fundamentals and applications. Int. Rev. Chem. Eng. 5, 102\u2013120 (2013).","journal-title":"Int. Rev. Chem. Eng."},{"key":"39569_CR51","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s13203-018-0199-4","volume":"8","author":"N Montoya S\u00e1nchez","year":"2018","unstructured":"Montoya S\u00e1nchez, N. & de Klerk, A. Autoxidation of aromatics. Appl. Petrochemical Res. 8, 55\u201378 (2018).","journal-title":"Appl. Petrochemical Res."},{"key":"39569_CR52","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2174\/1385272053369222","volume":"9","author":"MR Iesce","year":"2005","unstructured":"Iesce, M. R., Cermola, F. & Temussi, F. Photooxygenation of heterocycles. Curr. Org. Chem. 9, 109\u2013139 (2005).","journal-title":"Curr. Org. Chem."},{"key":"39569_CR53","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jpba.2007.02.037","volume":"44","author":"L Wu","year":"2007","unstructured":"Wu, L., Hong, T. Y. & Vogt, F. G. Structural analysis of photo-degradation in thiazole-containing compounds by LC\u2013MS\/MS and NMR. J. Pharm. Biomed. Anal. 44, 763\u2013772 (2007).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"39569_CR54","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jchromb.2012.01.018","volume":"887","author":"R Van Teijlingen","year":"2012","unstructured":"Van Teijlingen, R. et al. Development and validation of LC\u2013MS\/MS methods for the determination of mirabegron and its metabolites in human plasma and their application to a clinical Pharmacokinetic study. J. Chromatogr. B. 887, 102\u2013111 (2012).","journal-title":"J. Chromatogr. B"},{"key":"39569_CR55","unstructured":"Guidelines, I. C. H. Validation of analytical procedures: Text and methodology. Q2 (R1). (2005)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39569-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39569-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39569-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:03:00Z","timestamp":1781640180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39569-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["39569"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-39569-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9341"}}